Why Is Biomea Fusion (BMEA) Stock Down 63% Today?

This clinical hold comes from the Food and Drug Administration (FDA) and has to do with safety concerns. The regulator is worried about possible drug-induced hepatotoxicity. This comes after the trials may have led to liver enzyme elevations. Biomea Fusion chairman and CEO Thomas Butler said the following about this clinical hold news. How This Affects BMEA Stock Today Investors will want to stick around for even more of the most recent stock market stories on Friday! On the date of publication, William Whi ...